Compare DexCom, Inc. (DXCM) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Total Stock Market Index Fund ETF — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Vanguard Total Stock Market Index Fund ETF trades at $381.94 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 72.2× DexCom, Inc.'s market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| DXCM | VTI | |
|---|---|---|
Market Cap | $31.86B | $2.30T |
Volume | 3,607,070 | 2,982,924 |
Sector | Health | — |
52-Week High | $92.34 | $384.30 |
52-Week Low | $54.84 | $311.68 |
Typical Hold Time | 62 Days | 131 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth from $2.9B in 2022 to $4.66B in 2025. Profit margins have expanded significantly to 17.93%, while analyst sentiment remains overwhelmingly positive with 81% buy ratings. Recent news highlights the company's focus on Type 2 diabetes market expansion and leadership appointments.
DXCM presents a compelling growth story with expanding profitability and market opportunities, though elevated valuation multiples and technical bearish signals warrant caution. The consensus price target of $95.07 suggests 13% upside potential, but investors should monitor competitive pressures and reimbursement challenges in the CGM market.
VTI trades at $379.56, down 0.39% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF maintains strong institutional support and broad market exposure, though key financial ratios are unavailable in the current dataset. Recent news highlights VTI's long-term growth potential and diversification benefits compared to S&P 500-focused funds.
The outlook remains positive given VTI's low-cost structure and comprehensive U.S. equity coverage. Risks include concentration in top holdings and market volatility, but the ETF's historical performance supports its role as a core portfolio holding for long-term investors seeking total market exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
